The global biosimilars market is set for significant expansion in 2025, projected to reach between USD 21.95 billion and USD 42.53 billion.
Eli Lilly and Company declared today that Zepbound (tirzepatide), a popular weight-loss drug, will soon be offered in single-dose vials via LillyDirect Self Pay Pharmacy [Read More…]
CellCentric has secured $120 million in Series C funding to accelerate clinical development of Inobrodib, its first-in-class oral p300/CBP inhibitor for treating multiple myeloma. The investment will support upcoming Phase II/III trials and global expansion.
Compared to existing CAR T treatments, the off-the-shelf experimental therapeutic CTX112TM may allow for quicker patient access.
IQVIA reported $3.829 billion in total revenue for the first quarter that ended on March 31, 2025, a 2.5% increase over the same period in 2024.
Amgen Inc. (NASDAQ: AMGN) announced its financial results for the first quarter ended March 31, 2025, showcasing significant revenue growth fueled by strong product volume [Read More…]
Moderna, Inc. announced its financial results for the first quarter ending March 31, 2025, highlighting a strategic realignment towards oncology and other pipeline candidates amidst [Read More…]
Revenue reached $12.73 billion, a substantial 45% increase year-over-year, primarily fueled by strong volume growth from Mounjaro and Zepbound.
The gadget analyzes images using artificial intelligence to achieve a degree of diagnosis accuracy that is not achievable with conventional manual grading techniques.
Amgen has made about $5 billion in direct capital investments in the US since the Tax Cuts and Jobs Act of 2017 was passed.
